Abstract Since 2005, the Advisory Committee on Immunization Practices (ACIP) has
recommended a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) …

On July 8, 2011, the Food and Drug Administration (FDA) approved an expanded age
indication for the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine …

BACKGROUND: Pertussis can cause significant morbidity in elderly patients, who can also
transmit this disease to infants and young children. There is little data available on the use of …

Background Two Tdap vaccines are licensed for use in the United States. Boostrix
(GlaxoSmithKline) is approved for a single dose in persons aged≥ 10 years; Adacel (Sanofi …

BACKGROUND: Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap)
vaccine was not licensed for use in adults aged≥ 65 years due to lack of sufficient efficacy …

Compared with older children and adults, infants aged < 12 months have substantially
higher rates of pertussis and the largest burden of pertussis-related deaths. Since 2004, a …

Summary On June 10, 2005, a tetanus toxoid, reduced diphtheria toxoid and acellular
pertussis vaccine (Tdap) formulated for use in adults and adolescents was licensed in the …

Background. Published data on the safety of tetanus-diphtheria-acellular pertussis vaccine
(Tdap) in persons aged≥ 65 years are limited. This study aims to examine a large cohort of …

Despite sustained high coverage for childhood pertussis vaccination, pertussis remains
poorly controlled in the United States. A total of 16,858 pertussis cases and 12 infant deaths …

PURPOSE: This study was conducted to assess the immunogenicity and safety of a tetanus
toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine containing three …